Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Amgen Inc. won US approval for a new drug to treat a particularly aggressive form of advanced lung cancer, providing a badly ...
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The biosimilar carries a boxed warning on the increased risk of serious meningococcal infections. Credit: Melnikov Dmitriy / Shutterstock.com. The US Food and Drug Administration (FDA) has approved ...
Tarlatamab arrives after decades of no real treatment advances for this type of lung cancer. HealthDay News — The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung ...
AbbVie ABBV dosed the first patient with ABBV-383, an investigational BCMA-CD3-targeted bispecific antibody, in the phase III ...